News

Video

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Bradley McGregor, MD
Sairah Ahmed, M.D
Regina Barragan-Carrillo, MD
4 experts are featured in this series.
Brandon G. Smaglo, MD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Kathryn E. Beckermann, MD, PhD
Related Content
2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com
March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

Mark B. Geyer, MD, Adolescent and Young Adult Program leader, Adult Lymphoblastic Leukemia Program leader, Leukemia Service, chair, Quality Assessment, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
February 10th 2025

Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

Kidney Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy

Tivozanib/Nivolumab in RCC | Image Credit: © Crystal light – stock.adobe.com
March 4th 2025

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC